| Nonbiopsy diagnosis of cardiac transthyretin amyloidosis JD Gillmore, MS Maurer, RH Falk, G Merlini, T Damy, A Dispenzieri, ... Circulation 133 (24), 2404-2412, 2016 | 1723 | 2016 |
| Natural history and outcome in systemic AA amyloidosis HJ Lachmann, HJB Goodman, JA Gilbertson, JR Gallimore, CA Sabin, ... New England Journal of Medicine 356 (23), 2361-2371, 2007 | 1179 | 2007 |
| CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis JD Gillmore, E Gane, J Taubel, J Kao, M Fontana, ML Maitland, J Seitzer, ... New England Journal of Medicine 385 (6), 493-502, 2021 | 1099 | 2021 |
| Systemic amyloidosis AD Wechalekar, JD Gillmore, PN Hawkins The Lancet 387 (10038), 2641-2654, 2016 | 994 | 2016 |
| Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis HJ Lachmann, DR Booth, SE Booth, A Bybee, JA Gilbertson, JD Gillmore, ... New England Journal of Medicine 346 (23), 1786-1791, 2002 | 777 | 2002 |
| Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein JD Gillmore, LB Lovat, MR Persey, MB Pepys, PN Hawkins The Lancet 358 (9275), 24-29, 2001 | 722 | 2001 |
| Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases P Garcia-Pavia, C Rapezzi, Y Adler, M Arad, C Basso, A Brucato, ... European heart journal 42 (16), 1554-1568, 2021 | 670 | 2021 |
| ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2—evidence base and standardized methods of … S Dorbala, Y Ando, S Bokhari, A Dispenzieri, RH Falk, VA Ferrari, ... Circulation: Cardiovascular Imaging 14 (7), e000029, 2021 | 652* | 2021 |
| High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis A Jaccard, P Moreau, V Leblond, X Leleu, L Benboubker, O Hermine, ... New England Journal of Medicine 357 (11), 1083-1093, 2007 | 588 | 2007 |
| Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis M Fontana, S Pica, P Reant, A Abdel-Gadir, TA Treibel, SM Banypersad, ... Circulation 132 (16), 1570-1579, 2015 | 573 | 2015 |
| A new staging system for cardiac transthyretin amyloidosis JD Gillmore, T Damy, M Fontana, M Hutchinson, HJ Lachmann, ... European heart journal 39 (30), 2799-2806, 2018 | 546 | 2018 |
| Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy HJ Lachmann, R Gallimore, JD Gillmore, HD Carr‐Smith, AR Bradwell, ... British journal of haematology 122 (1), 78-84, 2003 | 540 | 2003 |
| A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis AD Wechalekar, SO Schonland, E Kastritis, JD Gillmore, MA Dimopoulos, ... Blood, The Journal of the American Society of Hematology 121 (17), 3420-3427, 2013 | 507 | 2013 |
| The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group N Leung, F Bridoux, V Batuman, A Chaidos, P Cockwell, VD D’Agati, ... Nature Reviews Nephrology 15 (1), 45-59, 2019 | 469 | 2019 |
| Native T1 mapping in transthyretin amyloidosis M Fontana, SM Banypersad, TA Treibel, V Maestrini, DM Sado, SK White, ... JACC: Cardiovascular Imaging 7 (2), 157-165, 2014 | 455 | 2014 |
| A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis G Palladini, S Sachchithanantham, P Milani, J Gillmore, A Foli, ... Blood, The Journal of the American Society of Hematology 126 (5), 612-615, 2015 | 424 | 2015 |
| Senile systemic amyloidosis: clinical features at presentation and outcome JH Pinney, CJ Whelan, A Petrie, J Dungu, SM Banypersad, ... Journal of the American Heart Association 2 (2), e000098, 2013 | 408 | 2013 |
| T1 mapping and survival in systemic light-chain amyloidosis SM Banypersad, M Fontana, V Maestrini, DM Sado, G Captur, A Petrie, ... European heart journal 36 (4), 244-251, 2015 | 403 | 2015 |
| Therapeutic clearance of amyloid by antibodies to serum amyloid P component DB Richards, LM Cookson, AC Berges, SV Barton, T Lane, JM Ritter, ... New England Journal of Medicine 373 (12), 1106-1114, 2015 | 401 | 2015 |
| Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis T Lane, M Fontana, A Martinez-Naharro, CC Quarta, CJ Whelan, A Petrie, ... Circulation 140 (1), 16-26, 2019 | 386 | 2019 |
Philip HawkinsProfessor of Medicine在 ucl.ac.uk 的电子邮件经过验证
Philip HawkinsProfessor of Medicine在 ucl.ac.uk 的电子邮件经过验证